OncologyRelacorilant + Nab-Paclitaxel vs Nab-Paclitaxel in Platinum-Resistant Ovarian Cancer: Pharmacokinetics and Pharmacokinetic/Pharmacodynamic Exposure-ResponseColombo et al. • 2026 • ESGO February 27, 2026
OncologyROSELLA: A Phase 3 Study of Relacorilant + Nab-Paclitaxel in Patients with Platinum-Resistant Ovarian Cancer (GOG-3073, ENGOT-ov72, APGOT-Ov10, LACOG-0223, and ANZGOG-2221/2023)Lorusso et al. • 2026 • ESGO February 26, 2026